A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

The invention relates to an animal feed additive comprising oligosaccharides, proteins, lipids, phenolic compounds and minerals, wherein the oligosaccharides comprise glucans, xylans, arabinans and mannans, and wherein degree of polymerisation (DP) of the oligosaccharides is DP1 to DP30 and to a method for preparing thereof from biomass.

The invention relates to an animal feed additive comprising oligosaccharides, proteins, lipids, phenolic compounds and minerals, wherein the oligosaccharides comprise glucans, xylans, arabinans and mannans, and wherein degree of polymerisation (DP) of the oligosaccharides is DP1 to DP30 and to a method for preparing thereof from biomass.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

The present invention provides a pharmaceutical composition including a probiotic and a prebiotic for treatment of stunting in children. More particularly, the pharmaceutical composition includes at least one Lactobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of treatment of stunting including administering an effective amount of a pharmaceutical composition including a probiotic and a prebiotic to children in need thereof.

The present invention provides a pharmaceutical composition including a probiotic and a prebiotic for treatment of stunting in children. More particularly, the pharmaceutical composition includes at least one Lactobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of treatment of stunting including administering an effective amount of a pharmaceutical composition including a probiotic and a prebiotic to children in need thereof.

The present invention provides a pharmaceutical composition including a probiotic and a prebiotic for treatment of stunting in children. More particularly, the pharmaceutical composition includes at least one Lactobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of treatment of stunting including administering an effective amount of a pharmaceutical composition including a probiotic and a prebiotic to children in need thereof.

The present invention includes a composition and method for preventing at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH) comprising: a compound of formula (I) and variants thereof:

##STR00001##

in an amount sufficient to prevent at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH).